Ycanth generics — when can they launch?
Ycanth (CANTHARIDIN) · Verrica Pharms · 4 active US patents · 0 expired
Where Ycanth sits in the generic timeline
Long-dated protection: earliest active US patent for Ycanth extends to 2035 (~9 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 3 patents
- Formulation — 1 patent
FDA U-codes carved out by Ycanth patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-3665 | (no description) |
U-3663 | (no description) |
Sample patent estate
Showing 4 of 4 active US patents. View full estate on the Ycanth drug page →
-
This patent protects devices, systems, methods, and kits for treating cutaneous diseases, such as warts, with a cantharidin formulation.USPTO title: Compositions, methods and systems for the treatment of cutaneous disorders
-
This patent provides methods for treating one or more skin lesions using cantharidin with minimal or no adverse side effects.USPTO title: Treatment of cutaneous disorders
-
This patent provides methods for treating one or more skin lesions using cantharidin, including compositions, treatment regimens, and devices.USPTO title: Treatment of cutaneous disorders
-
This patent protects devices and methods for treating body surface conditions by facilitating topical administration of a pharmaceutical composition, such as Ycanth.USPTO title: Devices and methods for the treatment of body surface disorders
Sources
- FDA Orange Book — patents listed against Ycanth (NDA filed 2023)
- Ycanth drug profile — full patent estate, indications, clinical trials, pricing
- Verrica Pharms patent portfolio
- Patent cliff 2035 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Ycanth — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →